WO2015046383A1 - Procédé pour produire un noyau contenant une substance médicamenteuse, noyau contenant une substance médicamenteuse, composition pharmaceutique et comprimé se désintégrant par voie orale - Google Patents

Procédé pour produire un noyau contenant une substance médicamenteuse, noyau contenant une substance médicamenteuse, composition pharmaceutique et comprimé se désintégrant par voie orale Download PDF

Info

Publication number
WO2015046383A1
WO2015046383A1 PCT/JP2014/075533 JP2014075533W WO2015046383A1 WO 2015046383 A1 WO2015046383 A1 WO 2015046383A1 JP 2014075533 W JP2014075533 W JP 2014075533W WO 2015046383 A1 WO2015046383 A1 WO 2015046383A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug substance
mass
parts
fluidized bed
orally disintegrating
Prior art date
Application number
PCT/JP2014/075533
Other languages
English (en)
Japanese (ja)
Inventor
佳紀 阪田
森　久容
雅洋 小谷
Original Assignee
富士フイルム株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 富士フイルム株式会社 filed Critical 富士フイルム株式会社
Priority to JP2015539355A priority Critical patent/JPWO2015046383A1/ja
Publication of WO2015046383A1 publication Critical patent/WO2015046383A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Definitions

  • the present invention relates to a method for producing a drug substance-containing nucleus, a drug substance-containing nucleus, a pharmaceutical composition, and an orally disintegrating tablet.
  • the drug substance or the pharmaceutical composition containing the drug substance is generally coated with a film, polymer, etc. to control the dissolution timing of the drug substance, mask the bitterness derived from the drug substance, etc. It has become.
  • orally disintegrating tablets are oral preparations that dissolve or disintegrate in the oral cavity immediately after taking, preparation techniques such as inhibition of drug substance degradation, bitterness masking, and dissolution adjustment are more important than normal oral preparations. become.
  • Japanese Patent Application Laid-Open No. 6-30975 discloses a method for granulating a drug substance capable of minimizing the size of a tablet by minimizing the addition amount of a component having an effect of suppressing adhesion and aggregation of the drug substance. Is described.
  • Japanese Patent Application Laid-Open No. 2006-131548 describes a method capable of efficiently producing highly stable particles when an unstable compound is used as a bulk powder.
  • Japanese Patent Application Laid-Open No. 2003-1091 describes a method capable of producing drug substance-containing particles of 50 ⁇ m to 200 ⁇ m and reducing the amount of spray liquid by using drug substance powder having an average particle diameter of 20 ⁇ m to 150 ⁇ m. Yes.
  • orally disintegrating tablets generally have a structure containing fine granules containing the drug substance (hereinafter also simply referred to as “fine granules”) and excipients outside the granules.
  • fine granules contained in an orally disintegrating tablet include a plurality of layers such as a drug substance-containing nucleus including a drug substance layer, an intermediate layer, and an elution control layer.
  • a drug substance-containing nucleus including a drug substance layer, an intermediate layer, and an elution control layer.
  • the present invention includes a method for producing a drug substance-containing nucleus that can improve the stability of the drug substance during and after the production of the drug substance-containing nucleus, the drug substance-containing nucleus obtained by this production method, and the drug substance-containing nucleus It is an object to provide a pharmaceutical composition.
  • the present invention also provides an orally disintegrating tablet containing clopidogrel sulfate or rabeprazole sodium as a drug substance, and containing a drug substance-containing nucleus that can improve the stability of the drug substance during and after the production of the drug substance-containing nucleus. This is the issue.
  • Means for solving the problems are as follows. ⁇ 1> Fluidized bed granulation of drug substance powder intermittently or continuously while the binder solution is intermittently or continuously charged into the fluidized bed granulator with the contents in the fluidized bed granulator fluidized. A method for producing a drug substance-containing nucleus having an average particle size of 100 ⁇ m to 500 ⁇ m, comprising putting into a granulator and granulating. ⁇ 2> The production method according to ⁇ 1>, comprising granulating while maintaining the ratio of the drug substance powder in the fluidized bed granulator to 10% by mass or less with respect to the total solids in the fluidized bed granulator.
  • ⁇ 3> The production method according to ⁇ 1> or ⁇ 2>, comprising setting the temperature in the fluidized bed granulator to 25 ° C. to 80 ° C.
  • ⁇ 4> The production method according to any one of ⁇ 1> to ⁇ 3>, wherein the drug substance-containing portion in the drug substance-containing nucleus contains 70% by mass to 100% by mass of the drug substance.
  • ⁇ 5> The production method according to any one of ⁇ 1> to ⁇ 4>, wherein the drug substance-containing portion in the drug substance-containing nucleus contains 0% by mass to 10% by mass of a binder.
  • ⁇ 6> The production method according to any one of ⁇ 1> to ⁇ 5>, wherein the drug substance powder has an average particle size of 0.1 ⁇ m to 20 ⁇ m.
  • ⁇ 7> A drug substance-containing nucleus obtained by the production method according to any one of ⁇ 1> to ⁇ 6>.
  • ⁇ 8> A pharmaceutical composition comprising the drug substance-containing nucleus according to ⁇ 7>.
  • ⁇ 9> An orally disintegrating tablet, wherein the drug substance-containing core contains particulate clopidogrel sulfate or particulate rabeprazole sodium, and the drug substance-containing nucleus has an average particle size of 100 ⁇ m to 500 ⁇ m.
  • ⁇ 10> The orally disintegrating tablet according to ⁇ 9>, wherein the drug substance-containing portion in the drug substance-containing nucleus contains 70% by mass to 100% by mass of clopidogrel sulfate or rabeprazole sodium.
  • ⁇ 11> The orally disintegrating tablet according to ⁇ 9> or ⁇ 10>, wherein the drug substance-containing portion in the drug substance-containing core contains 0% by mass to 10% by mass of a binder.
  • the ratio (D90 / D10) of the particle size (D90) having a cumulative volume percentage of 90% to the particle size (D10) having a cumulative volume percentage of 10% of the drug substance-containing nucleus is 4.0 or less.
  • ⁇ 13> The orally disintegrating tablet according to any one of ⁇ 9> to ⁇ 12>, wherein the water content is 1.0% by mass or less.
  • a method for producing a drug substance-containing nucleus that can improve the stability of the drug substance during and after the production of the drug substance-containing nucleus, the drug substance-containing nucleus obtained by this production method, and the drug substance-containing nucleus can be provided.
  • an orally disintegrating tablet comprising clopidogrel sulfate or rabeprazole sodium as a drug substance, and comprising a drug substance-containing nucleus that can improve the stability of the drug substance during and after the production of the drug substance.
  • Example 1 is a volume frequency distribution diagram showing a particle size distribution of drug substance powder according to Example 1.
  • FIG. It is the volume frequency distribution figure which showed the particle size distribution of the drug substance powder concerning Example 2.
  • 6 is a photograph of a drug substance-containing nucleus according to Example 3.
  • 2 is a photograph of a drug substance-containing nucleus according to Comparative Example 1.
  • a numerical range indicated using “to” indicates a range including the numerical values described before and after “to” as the minimum value and the maximum value, respectively.
  • the amount of each component in the composition is the total amount of the plurality of substances present in the composition unless there is a specific indication when there are a plurality of substances corresponding to each component in the composition.
  • “(meth) acrylic acid” represents both or one of acrylic acid and methacrylic acid.
  • the term “process” is not limited to an independent process, and is included in the term if the intended purpose of the process is achieved even when it cannot be clearly distinguished from other processes.
  • the “average particle diameter” indicates a volume average particle diameter.
  • a measuring method of the average particle diameter there is a laser diffraction particle size distribution measuring method, and a specific example is a method using a laser diffraction scattering particle size distribution measuring device (product name: LS 13 320, manufactured by Beckman Coulter, Inc.). It is done.
  • particle granulation methods are roughly classified into wet granulation in which particles are formed by introducing a liquid such as a binding liquid and dry granulation in which no liquid is used.
  • wet granulation include fluidized bed granulation, stirring granulation, and spray drying.
  • dry granulation include compression granulation and pulverization granulation.
  • fluidized bed granulation include rolling fluidized bed granulation and spouted fluidized bed granulation.
  • the drug substance powder is added while intermittently or continuously charging the binding liquid into the fluid bed granulator. It includes intermittently or continuously feeding into a fluidized bed granulator and granulating (hereinafter also referred to as “granulating step”).
  • granulating step By supplying the drug substance powder intermittently or continuously to the fluidized bed granulator, the storage stability of the drug substance during and after the production of the drug substance-containing nucleus can be improved.
  • the method for producing a drug substance-containing nucleus of the present invention may further include other steps as necessary.
  • the drug substance powder is intermittently or continuously flowed while the binder solution is intermittently or continuously charged into the fluidized bed granulator while the contents in the fluidized bed granulator are flowing. It includes putting into a layer granulator and granulating.
  • the drug substance powder may be added intermittently or continuously while charging the binding liquid into the fluidized bed granulator, or the charging of the binding liquid is stopped halfway and intermittently or continuously. Alternatively, the drug substance powder may be added and the binding solution may be charged again.
  • the drug substance dissolved during the granulation step can be prevented from being decomposed. Further, in the granulation step, the storage stability of the drug substance after the production of the drug substance-containing nucleus can be improved.
  • the drug substance-containing core contains particulate drug substance, so that the drug substance and water, oxygen, binder, etc. It is believed that contact is reduced, but the scope of the present invention is not limited to this mechanism.
  • the method for charging the binding liquid into the fluidized bed granulator is not particularly limited, and may be a known method such as spraying or dropping, and it is preferable to spray the binding liquid into the fluidized bed granulator.
  • the input amount of the binding liquid may be adjusted according to the type and amount of the drug substance powder to be input to the fluidized bed granulator. For example, when clopidogrel sulfate is used as the drug substance powder, the input amount of the binding solution should be 300% by mass to 30% by mass with respect to the total mass of the drug substance powder charged into the fluidized bed granulator. It is preferably 250 mass% to 40 mass%, more preferably 150 mass% to 50 mass%.
  • the temperature in the fluidized bed granulator is preferably 25 ° C to 80 ° C. It is preferable to set the temperature in the fluidized bed granulator to 25 ° C. or higher because decomposition due to moisture in the drug substance contained in the granulated product can be reduced. It is preferable to set the temperature in the fluidized bed granulator to 80 ° C. or lower because decomposition of the drug substance contained in the granulated product due to heat can be reduced.
  • the temperature in the fluidized bed granulator is more preferably 30 ° C. to 60 ° C., and further preferably 30 ° C. to 40 ° C.
  • the moisture in the granulated product can be measured with a heat-drying moisture meter (A & D Co., Ltd.), a Karl Fischer moisture meter (Mitsubishi Chemical Analytech Co., Ltd.) or the like.
  • a heat-drying moisture meter A & D Co., Ltd.
  • a Karl Fischer moisture meter Mitsubishi Chemical Analytech Co., Ltd.
  • the water content of the granulated product in the fluidized bed granulator is 1 to It is desirable to maintain 0.0 mass% or more, and in order to suppress decomposition, it is more desirable to maintain 2.5 mass% or less with respect to the total solid content of the granulated product.
  • the drug substance powder may be intermittently or continuously charged into the fluidized bed granulator.
  • the method for charging the drug substance powder is not particularly limited, and may be a known method.
  • the timing of loading the drug substance powder into the fluidized bed granulator is when the ratio of the drug substance powder in the fluidized bed granulator becomes 10% by mass or less with respect to the total solids in the fluidized bed granulator. Preferably, it is more preferably 5% by mass or less, and even more preferably 1% by mass or less.
  • the ratio of the drug substance powder in the fluidized bed granulator can be measured by sieving using a sieve, laser diffraction type particle size distribution measuring method or the like.
  • a part of the solids in the fluidized bed granulator is extracted, and the mass% of the particles that have passed through the sieve is measured with respect to the total extraction amount using a sieve having an opening of about the maximum particle size of the drug substance powder.
  • the measured value is defined as the ratio of the drug substance powder in the fluidized bed granulator. It is preferable to use the dry mass excluding moisture as the total extraction amount and the mass of the particles that have passed through the sieve.
  • the solid matter in the fluidized bed granulator is extracted and measured immediately, and is converted in advance. You may convert into the mass% at the time of drying using a type
  • ratio of drug substance powder in fluidized bed granulator means a component of drug substance powder existing in fluidized bed granulator that can be a raw material of drug substance-containing core present in fluidized bed granulator Of the total solids.
  • the amount of the drug substance powder is controlled by suppressing the granulation of the drug substance powders that have been charged, Since it is desirable to bind to the granulated material in the bed granulator, it is preferably 10% by mass or less, more preferably 5% by mass or less, and still more preferably 1% by mass or less based on the total solids in the fluidized bed granulator. .
  • the drug substance powder feed rate is determined by the fluid bed granulator capacity, the type of drug substance, the particle diameter of the drug substance powder, the binding liquid. It can be set as appropriate depending on the type of the above.
  • the ratio of the drug substance powder in the fluidized bed granulator is preferably maintained at 10% by mass or less with respect to the total solids in the fluidized bed granulator, and can be maintained at 5% by mass or less. More preferably, it is more preferably maintained at 1% by mass or less.
  • the ratio of the drug substance powder in the fluidized bed granulator to 10% by mass or less with respect to the total solids in the fluidized bed granulator, the granulation of the charged drug substance powders is suppressed and charged.
  • the resulting drug substance powder binds to the granulated material present in the fluidized bed granulator, and the drug substance-containing core showing a sharp shape in the particle size distribution can be granulated.
  • drug substance powder refers to a drug substance whose surface is not wet with a binding liquid, or a free drug substance that is not bound to a core particle, a drug substance-containing nucleus, a fluidized bed granulator, etc., which will be described later. Means.
  • the ratio of the binding liquid and the drug substance powder charged into the fluidized bed granulator is preferably 3: 1 to 1: 3 on a mass basis (binding liquid: drug substance powder).
  • binding liquid drug substance powder
  • the ratio of the binding liquid and the drug substance powder is more preferably 2.5: 1 to 1: 2.5, based on mass (binding solution: drug substance powder), and 2: 1 to 1: 2. Is more preferable.
  • Examples of the fluidized bed granulator include, for example, a fluidized bed granulator (product name: FD-MP-01, manufactured by POWREC), a flow coater (product name: FL-1, manufactured by Freund Sangyo Co., Ltd.) Is mentioned.
  • a fluidized bed granulator product name: FD-MP-01, manufactured by POWREC
  • a flow coater product name: FL-1, manufactured by Freund Sangyo Co., Ltd.
  • the binding liquid is not particularly limited, and a known binding liquid used for fluidized bed granulation can be used.
  • the binding liquid for example, water or an organic solvent may be used as it is, or a binding liquid in which a binder is dissolved, dispersed, or suspended in water or an organic solvent may be used.
  • the binder may not be included.
  • the binding liquid may contain other components such as a component that can function as an excipient, a component that can function as a lubricant, and a fluidizing agent.
  • the organic solvent include methanol, ethanol, propanol, isopropanol and the like.
  • the binder is an additive used for imparting a binding force to a mixed granular material such as a main agent and a bulking agent and molding the mixture.
  • binders include hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, low-substituted hydroxypropylcellulose, carboxyvinyl polymer, carmellose sodium, pregelatinized starch, polyvinylpyrrolidone, gum arabic powder, gelatin, pullulan, polyvinyl alcohol and the like. It is done.
  • the component that can function as an excipient include sugar, sugar alcohol, crystalline cellulose, starch and the like.
  • Examples of the sugar include lactose, sucrose, maltose, trehalose, dextrin and the like.
  • Examples of the sugar alcohol include mannitol, erythritol, isomalt, lactitol, maltitol, sorbitol, xylitol and the like.
  • Examples of the starch include corn starch, potato starch, rice starch, wheat starch and the like.
  • Examples of components that can function as a lubricant and a fluidizing agent include talc and light anhydrous silicic acid.
  • the amount of the binder dissolved, dispersed, or suspended in the solvent can be appropriately set depending on the type of drug substance, the amount of drug substance, the particle diameter of the drug substance powder, and the like.
  • the binding liquid examples include a binding liquid in which 0% by mass to 10% by mass of a binder is added to the total mass of the solvent, a binding liquid in which 0% by mass to 5% by mass is added, and 0% by mass to 3% by mass. And the like.
  • the binder content of the binding solution is preferably as small as possible in the range in which the drug substance can be granulated.
  • the binder content of the binding liquid is preferably 0% by mass to 5% by mass, and more preferably 0.01% by mass to 3% by mass.
  • the binder content of the drug substance-containing portion (in the drug substance layer) in the drug substance-containing nucleus is preferably 0% by mass to 10% by mass.
  • the drug substance (hereinafter also referred to as “active ingredient”) is not particularly limited, and is not limited to antiplatelet drugs, antiulcer drugs, antipsychotic drugs, bronchial asthma drugs, allergic rhinitis drugs, antihypertensive drugs, hypercholesterolemia Drugs, antidepressants, antihistamines, antibacterial agents, osteoporosis drugs, diabetes drugs, diuretics, antirheumatic drugs, and the like.
  • the antiplatelet drug include clopidogrel sulfate, ticlopidine, prosugrel hydrochloride, cilostazol and the like.
  • anti-ulcer agent examples include proton pump inhibitors such as benzimidazole compounds such as rabeprazole, omeprazole, lansoprazole, pantoprazole or salts thereof; histamine H2 receptor antagonists such as famotidine, cimetidine, ranitidine hydrochloride, and the like.
  • antipsychotics include olanzapine, duloxetine, risperidone, quetiapine and the like.
  • bronchial asthma therapeutic agents or allergic rhinitis therapeutic agents include montelukast sodium and pranlukast.
  • antihypertensive agents examples include telmisartan, olmesartan medoxomil, valsartan, amlodipine besylate, and the like.
  • hypercholesterolemia examples include fluvastatin sodium and colestimide.
  • antidepressant examples include imipramine, maprotiline hydrochloride, amphetamine and the like.
  • antihistamine examples include diphenhydramine hydrochloride, promethazine, isothipentyl hydrochloride, dl-chlorpheniramine maleate, and the like.
  • Antibacterial agents include penicillin, ampicillin, erythromycin, clarithromycin, vancomycin and the like.
  • osteoporosis agent examples include ipriflavone and the like.
  • diabetes drug examples include tolbutamide, voglibose, pioglitazone hydrochloride, glibenclamide, troglitazone, rosiglitazone maleate, acarbose, miglitol, emiglitate, and the like.
  • diuretics include thiazide agents such as isosorbide, furosemide, and HCTZ (hydrochlorothiazide).
  • antirheumatic drugs include methotrexate and bucillamine.
  • clopidogrel sulfate or fluvastatin sodium is preferred as the drug substance from the viewpoint that it has bitterness and is unstable to water, so that the effects of the present invention can be fully exerted.
  • Clopidogrel sulfate A salt is more preferred.
  • the drug substance is preferably a benzimidazole compound such as rabeprazole, lansoprazole, omeprazole, pantoprazole, or a salt thereof, from the viewpoint that the effects of the present invention can be fully exhibited, and rabeprazole sodium Is more preferable.
  • the average particle size of the drug substance powder is preferably 0.1 ⁇ m to 20 ⁇ m.
  • the average particle diameter of the drug substance powder is more preferably 2 ⁇ m to 15 ⁇ m, and still more preferably 5 ⁇ m to 10 ⁇ m.
  • Disintegrants include starch such as corn starch and potato starch, partially pregelatinized starch, carboxymethyl starch sodium, carmellose, carmellose calcium, croscarmellose sodium, crospovidone, low-substituted hydroxypropylcellulose, crystalline cellulose, hydroxypropyl And starch.
  • a granulated product with a sharp particle size distribution is obtained by using core particles with a sharp particle size distribution and a particle size larger than that of the drug substance powder.
  • Obtainable by using core particles having a particle size larger than that of the drug substance powder, aggregation between particles can be suppressed, and a highly spherical granulated product can be obtained.
  • the core particles only need to contain at least one selected from the group consisting of the drug substance and other components.
  • the core particles may contain only the drug substance, may contain the drug substance and other components, or may contain only other components.
  • the raw powder (the drug substance powder) itself may be used, a granulated product may be used, or commercially available core particles may be used.
  • Non-parrel manufactured by Freund Sangyo Co., Ltd.
  • Selfia manufactured by Asahi Kasei Chemicals Co., Ltd.
  • commercially available core particles are listed as commercially available core particles.
  • the drug substance content in the drug substance-containing portion (in the drug substance layer) of the drug substance-containing nucleus is 70% by mass to 100% by mass. If the drug substance content in the drug substance-containing core (in the drug substance layer) is lower than 70% by mass, it is not preferable because it may lead to a decrease in dosage due to an increase in tablet diameter.
  • the drug substance content of the drug substance-containing portion (in the drug substance layer) in the drug substance-containing nucleus is more preferably 80% by mass to 100% by mass, and still more preferably 90% by mass to 100% by mass. .
  • the average particle size of the drug substance-containing nucleus is 100 ⁇ m to 500 ⁇ m.
  • the average particle size of the drug substance-containing nucleus is adjusted to a range of 100 ⁇ m to 500 ⁇ m, so that when the orally disintegrating tablet disintegrates in the oral cavity, The roughness in the inside can be reduced.
  • the average particle size of the drug substance-containing nucleus is preferably 100 ⁇ m to 350 ⁇ m, more preferably 150 ⁇ m to 250 ⁇ m.
  • the drug substance content of the drug substance-containing portion (in the drug substance layer) in the drug substance-containing nucleus is 70% by mass to 100% by mass
  • the size of the orally disintegrating tablet can be made smaller than that of the conventional orally disintegrating tablet.
  • the drug substance-containing nucleus obtained by the granulation process can be used for the preparation of a pharmaceutical composition.
  • the pharmaceutical composition include tablets, capsules, powders, granules, fine granules, dry syrups, etc. Among them, tablets are preferable.
  • the drug substance-containing nucleus can be particularly preferably used for the preparation of orally disintegrating tablets.
  • an orally disintegrating tablet can be obtained by coating the drug substance-containing core with an intermediate layer and further coating the intermediate layer with an elution control layer.
  • a specific method for producing the orally disintegrating tablet may be in accordance with a known method, for example, according to the method described in JP2012-162502A.
  • the orally disintegrating tablet of the present invention contains particulate clopidogrel sulfate or particulate rabeprazole sodium in the drug substance-containing portion of the drug substance-containing nucleus, and the drug substance-containing nucleus has an average particle size of 100 ⁇ m to 500 ⁇ m.
  • the thickness is preferably 100 ⁇ m to 350 ⁇ m, more preferably 150 ⁇ m to 250 ⁇ m.
  • the orally disintegrating tablet may contain other components or other layers as necessary.
  • the water content of the orally disintegrating tablet of the present invention is preferably 1.5% by mass or less.
  • the water content of the orally disintegrating tablet is more preferably 1.0% by mass or less, and further preferably 0.5% by mass or less.
  • the water content of the orally disintegrating tablet can be suppressed by drying the orally disintegrating tablet before packaging the orally disintegrating tablet.
  • the method for drying the orally disintegrating tablet is not particularly limited, and the orally disintegrating tablet can be dried by a method of supplying air dried to a relative humidity of 5% or less at a temperature of 25 ° C. for several hours.
  • a known dryer can be applied, and examples thereof include a dry dehumidifier (trade name: Honey Dry, (Daikin Co., Ltd.) and the like.
  • the orally disintegrating tablet of the present invention contains a drug substance-containing nucleus.
  • the drug substance-containing nucleus only needs to contain the drug substance-containing portion (the drug substance layer), and may contain nucleus particles.
  • the content ratio of clopidogrel sulfate or rabeprazole sodium contained in the drug substance layer is preferably in the range of 70% by mass to 100% by mass with respect to the total mass of the components forming the drug substance layer. By setting it as this range, the size of the orally disintegrating tablet can be made smaller than that of the conventional orally disintegrating tablet.
  • the content ratio of clopidogrel sulfate or rabeprazole sodium contained in the drug substance layer is more preferably 80% by mass to 100% by mass with respect to the total mass of the components forming the drug substance layer, and 90% by mass. More preferably, it is ⁇ 100% by mass.
  • the orally disintegrating tablet of the present invention contains particulate clopidogrel sulfate or rabeprazole sodium in the drug substance layer.
  • particulate clopidogrel sulfate or rabeprazole sodium in the drug substance layer, the storage stability of clopidogrel sulfate or rabeprazole sodium is improved.
  • the drug substance layer containing particulate clopidogrel sulfate or rabeprazole sodium is fluidized bed granulated using a binding solution not containing clopidogrel sulfate or rabeprazole sodium and a drug substance powder of clopidogrel sulfate or rabeprazole sodium. Can be obtained.
  • particulate drug substance in the drug substance-containing nucleus can be confirmed by observation of the drug substance-containing nucleus with an optical microscope. It is clear that the particulate drug substance is contained in fine granules or orally disintegrating tablets produced using a drug substance-containing core containing the particulate drug substance. The fact that the granular drug substance is contained in the fine granules or orally disintegrating tablets indicates that the cut surfaces of these fine granules or orally disintegrating tablets are observed by observation with a scanning electron microscope (SEM). It can also be confirmed by confirming the shape structure or by structural analysis by X-ray CT (Computed Tomography).
  • SEM scanning electron microscope
  • the particle size of the drug substance contained in the drug substance-containing nucleus is preferably 0.1 ⁇ m to 20 ⁇ m, more preferably 2 ⁇ m to 15 ⁇ m, and even more preferably 5 ⁇ m to 10 ⁇ m.
  • the drug substance layer may contain other components in addition to the drug substance. Examples of other components include excipients, binders, disintegrants, lubricants, fluidizing agents, and the like.
  • the content of the binder in the drug substance-containing portion (the drug substance layer) in the drug substance-containing nucleus is preferably 0% by mass to 10% by mass with respect to the total mass of the components forming the drug substance layer.
  • the drug substance-containing nucleus may contain nuclear particles.
  • the core particles only need to contain at least one selected from the group consisting of the drug substance and other components.
  • the core particles may contain only the drug substance, may contain the drug substance and other components, or may contain only other components.
  • the raw powder (the drug substance powder) itself may be used, a granulated product may be used, or commercially available core particles may be used.
  • Non-parrel manufactured by Freund Sangyo Co., Ltd.
  • Selfia manufactured by Asahi Kasei Chemicals Co., Ltd.
  • the like are listed as commercially available core particles.
  • the ratio (D90 / D10) of the 90% cumulative volume percentage (D90) to the 10% cumulative volume percentage (D10) of the drug substance-containing nucleus is preferably 4.0 or less.
  • D90 / D10 is 4.0 or less, roughness in the mouth can be suppressed and the feeling of dosing when an orally disintegrating tablet is contained in the mouth can be improved.
  • the particle size at 10% of the cumulative volume percentage curve that is, 10% of the total volume when accumulated from the smaller particle size, is obtained from the size distribution of the particle size obtained at the time of measuring the average particle size.
  • the corresponding particle size is defined as “D10”.
  • the particle size at 90% of the cumulative volume percentage curve that is, 90% of the total volume when accumulated from the smaller particle size size, from the size distribution of the particle size obtained at the time of measuring the average particle size.
  • the particle size corresponding to% is defined as “D90”.
  • the orally disintegrating tablet of the present invention preferably contains a drug substance-containing nucleus obtained according to the above-described method for producing a drug substance-containing nucleus, but is not limited thereto.
  • the orally disintegrating tablet preferably comprises an intermediate layer and an elution control layer in addition to the drug substance-containing core.
  • the intermediate layer is a layer that covers the drug substance-containing nucleus and prevents contact between the release control layer and the drug substance-containing nucleus.
  • the orally disintegrating tablet preferably has at least one intermediate layer.
  • the intermediate layer may be a multilayer of two or more layers.
  • the form in which the intermediate layer covers the drug substance-containing nucleus may be in a state where the intermediate layer exists on at least a part of the surface of the drug substance-containing nucleus.
  • the intermediate layer preferably covers 1/4 or more of the surface of the drug substance-containing nucleus, more preferably covers 1/2 or more, and most preferably covers the whole.
  • the component forming the intermediate layer is not particularly limited, and known components can be used in the orally disintegrating tablet.
  • components that can form the intermediate layer include water-soluble polymers and water-insoluble polymers.
  • components that can form an intermediate layer other than these components include excipients, binders, disintegrants, lubricants, fluidizing agents, and the like.
  • the water-soluble polymer examples include water-soluble cellulose derivatives, water-soluble vinyl polymer derivatives, water-soluble acrylic acid copolymers, polyhydric alcohol polymers, and copolymers thereof (hereinafter referred to as “copolymer polymers”). Also called).
  • the water-soluble polymer is preferably a water-soluble polymer selected from the group consisting of a water-soluble cellulose derivative and a water-soluble vinyl polymer derivative, and more preferably a water-soluble cellulose derivative. More specifically, examples of the water-soluble cellulose derivative include methyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose and the like.
  • Examples of the water-soluble vinyl polymer derivative include polyvinyl alcohol and polyvinyl pyrrolidone.
  • water-soluble acrylic acid copolymer examples include polymers that contain acrylic acid, acrylic acid ester, methacrylic acid ester, and the like and that can be dissolved in any of acidic, neutral, and alkaline aqueous solutions.
  • Examples of the polyhydric alcohol polymer include macrogol and polyglycerin.
  • Examples of the copolymer include polyvinyl alcohol / acrylic acid / methyl methacrylate copolymer, polyethylene glycol / polyvinyl alcohol graft copolymer, vinyl pyrrolidone / vinyl alcohol copolymer, and the like.
  • water-soluble polymer a water-soluble cellulose derivative selected from the group consisting of hydroxypropylmethylcellulose and hydroxypropylcellulose is preferable from the viewpoint of viscosity and binding property suitable for fine particle coating.
  • a commercially available product may be used as the water-soluble polymer.
  • water-soluble polymers examples include polyvinyl alcohol / acrylic acid / methyl methacrylate copolymer (trade name: POVACOAT, manufactured by Daido Kasei Kogyo Co., Ltd.), polyethylene glycol / polyvinyl alcohol graft copolymer (product) Name: Kollicoat IR, manufactured by BASF), vinylpyrrolidone / vinyl alcohol copolymer (trade name: Kollicoat VA64, manufactured by BASF), and the like. Any one water-soluble polymer may be used alone, or two or more water-soluble polymers may be used in combination.
  • the content of the water-soluble polymer contained in the intermediate layer can be appropriately determined in consideration of the type of the active ingredient, the content of the active ingredient, the daily dose of the active ingredient, the particle size of the fine particles, and the like.
  • the content of the water-soluble polymer is 0% by mass to 100% by mass, 15% by mass to 80% by mass, 30% by mass to 60% by mass, etc. with respect to the total mass of the film components forming the intermediate layer. be able to.
  • the water-insoluble polymer contained in the intermediate layer is not particularly limited as long as it is a component that does not depend on the pH value of the contacted aqueous solution and does not dissolve in any of the acidic, neutral, and alkaline aqueous solutions. Polymers can be used.
  • the water-insoluble polymer is preferably a polymer that controls the elution of the active ingredient, for example, by slowly releasing the coated active ingredient after the elution control layer covering the intermediate layer is dissolved in the stomach or intestine.
  • water-insoluble polymer means a polymer having a solubility in water at 20 ° C. of less than 10 g / L.
  • water-insoluble polymer examples include water-insoluble cellulose ether and water-insoluble acrylic acid copolymer.
  • water-insoluble cellulose ether examples include ethyl cellulose.
  • water-insoluble acrylic acid copolymer examples include ethyl acrylate / methyl methacrylate / methacrylated trimethylammonium ethyl copolymer, ethyl acrylate / methyl methacrylate copolymer dispersion, and the like.
  • a commercially available product can also be used as the water-insoluble polymer.
  • examples of commercially available water-insoluble cellulose ethers examples include ethylcellulose aqueous dispersions (trade name: Aquacoat ECD, manufactured by FMC).
  • water-insoluble acrylic acid copolymers include ethyl acrylate / methyl methacrylate / methacrylic acid trimethylammonium ethyl copolymer (trade name: Eudragit RS, Evonik (Evonik Rohm GmbH)), ethyl acrylate. / Methyl methacrylate copolymer dispersion (trade name: Eudragit NE30D, manufactured by Evonik).
  • the water-insoluble polymer any one of the water-insoluble polymers may be used alone, or two or more kinds may be used in combination.
  • the content of the water-insoluble polymer contained in the intermediate layer can be appropriately determined in consideration of the type of the active ingredient, the content of the active ingredient, the daily dose of the active ingredient, the particle size of the fine particles, and the like.
  • the content of the water-insoluble polymer is 0% by mass to 100% by mass, 15% by mass to 80% by mass, 30% by mass to 60% by mass, etc. with respect to the total mass of the components forming the intermediate layer. Can do.
  • the intermediate layer may contain other components in addition to the polymer as long as the effects of the present invention are not impaired.
  • other components include excipients, binders, disintegrants, lubricants, fluidizing agents, and the like. These other components may be components in which one component assumes two or more functions.
  • the coating amount of the intermediate layer when coating the drug substance-containing nucleus with the intermediate layer is not particularly limited as long as it is an amount in which the drug substance-containing nucleus is covered with the intermediate layer.
  • the mass of the intermediate layer used for coating the drug substance-containing nucleus is 0.01 to 50 times, 0.1 to 5 times, or 0. The amount is 3 times to 1 time.
  • a component that forms an intermediate layer having a double mass may be dissolved or suspended in a pharmacologically acceptable solvent and sprayed onto the drug substance-containing nucleus.
  • a plurality of intermediate layer coating liquids having different compositions may be sprayed on the drug substance-containing core in a plurality of times for each intermediate layer coating liquid.
  • the elution control layer means a film that imparts timed release or sustained release to a preparation. Specifically, as an elution control layer, a gastric film and an enteric film that release the active ingredient at the target site by changing the solubility according to the pH of the liquid in contact, dissolved in water in a certain time In the meantime, water-soluble membranes that prevent the release of active ingredients, water-insoluble membranes that slowly release active ingredients due to low water solubility or water insolubility, and the functions of these membranes are combined Examples include membranes.
  • the elution control layer may be formed of one or more layers, and may be a multilayer such as two layers.
  • the component that forms the elution control layer is not particularly limited, and known components can be used in the orally disintegrating tablet.
  • the gastric film is not particularly limited as long as it is formed of components that dissolve in an acidic aqueous solution but do not dissolve in a basic aqueous solution.
  • the gastric film include a film formed of components such as a gastric soluble polyvinyl derivative and a gastric soluble acrylic acid copolymer.
  • the gastric soluble polyvinyl derivative include polyvinyl acetal diethylaminoacetate.
  • gastric soluble acrylic acid copolymer examples include methyl (meth) acrylate / butyl (meth) acrylate / dimethylaminoethyl (meth) acrylate, methyl methacrylate / diethylaminoethyl methacrylate copolymer, etc. Is mentioned.
  • Commercially available products may be used as the gastric soluble polyvinyl derivative and the gastric soluble acrylic acid copolymer.
  • gastric soluble polyvinyl derivatives examples include polyvinyl acetal diethylaminoacetate (trade name: AEA, manufactured by Mitsubishi Chemical Food Co., Ltd.).
  • gastric acrylic copolymers include, for example, methyl methacrylate / butyl methacrylate / dimethylaminoethyl methacrylate copolymer (trade names: Eudragit E100, Eudragit EPO, manufactured by Evonik), methyl methacrylate / Examples include diethylaminoethyl methacrylate copolymer (trade name: Kollicoat Smartseal 30D, manufactured by BASF).
  • the gastric soluble membrane may be formed by using any one component alone, or by combining two or more components having similar properties or two or more components having different properties. May be formed.
  • the gastric film can be formed so as to have a multilayer structure, for example.
  • the content of the gastric film can be 5% by mass to 70% by mass, 10% by mass to 60% by mass, 15% by mass to 50% by mass, etc. with respect to the total mass of the fine granules.
  • the enteric membrane is not particularly limited as long as it is formed of components that dissolve in a basic aqueous solution but do not dissolve in an acidic aqueous solution.
  • the enteric membrane is preferably an enteric membrane containing an aqueous enteric polymer.
  • Examples of the component that dissolves in the basic aqueous solution and does not dissolve in the acidic aqueous solution include enteric polymers such as enteric cellulose derivatives and enteric acrylic acid copolymers.
  • enteric cellulose derivative include hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose phthalate, carboxymethylethylcellulose, and the like.
  • the enteric acrylic copolymer examples include a methacrylic acid copolymer, and specifically, a methacrylic acid / methyl methacrylate copolymer, a methacrylic acid / ethyl acrylate copolymer, and a methyl acrylate / methacrylic acid. And methyl / methacrylic acid copolymer.
  • a methacrylic acid copolymer is preferable as a component for forming an enteric film from the viewpoint of easy coating of fine particles with a low viscosity even at a high concentration.
  • Commercially available products can be used as the enteric cellulose derivative and the enteric acrylic acid copolymer.
  • enteric cellulose derivatives examples include hydroxypropyl methylcellulose acetate succinate (trade name: HPMCAS, manufactured by Shin-Etsu Chemical Co., Ltd.), hydroxypropyl methylcellulose phthalate (trade name: HPMCP, manufactured by Shin-Etsu Chemical Co., Ltd.). ), Carboxymethyl ethyl cellulose (trade name: CMEC, manufactured by Freund Sangyo Co., Ltd.) and the like.
  • enteric acrylic acid copolymers examples include methacrylic acid / methyl methacrylate copolymers (trade names: Eudragit L100, Eudragit S, manufactured by Evonik), methacrylic acid / ethyl acrylate copolymers (commodities) Name: Eudragit L100-55, Eudragit L30D55, manufactured by Evonik), methyl acrylate / methyl methacrylate / methacrylic acid copolymer (trade name: Eudragit FS30D, manufactured by Evonik), and the like.
  • Water-based enteric polymer refers to an enteric polymer that can be sprayed as an aqueous solution or dispersion.
  • examples of the aqueous enteric polymer include hydroxypropyl methylcellulose acetate succinate, methacrylic acid / ethyl acrylate copolymer, and methyl acrylate / methyl methacrylate / methacrylic acid copolymer.
  • An enteric membrane may be formed by using any one component alone depending on the purpose, and two or more components having similar properties or two or more components having different properties may be used in combination. May be formed.
  • the enteric film can be formed to have a multilayer structure.
  • the content of the enteric membrane can be 5% by mass to 70% by mass, 10% by mass to 60% by mass, 15% by mass to 50% by mass, etc. with respect to the total mass of the fine granules.
  • the water-soluble film is not particularly limited as long as it is a film formed of a water-soluble polymer that dissolves in water after a certain period of time after the film is immersed in water at 20 ° C.
  • the certain time can be appropriately set according to the dissolution time required for the water-soluble film.
  • Examples of the fixed time include 0 hours to 48 hours, 0 hours to 24 hours, 0 hours to 12 hours, and the like.
  • Specific examples of the water-soluble polymer include water-soluble cellulose derivatives, water-soluble vinyl polymer derivatives, water-soluble acrylic acid copolymers, polyhydric alcohol polymers, and copolymers thereof (hereinafter referred to as “copolymer polymers”). ”)").
  • the water-soluble polymer is preferably a water-soluble polymer selected from the group consisting of a water-soluble cellulose derivative and a water-soluble vinyl polymer derivative, and more preferably a water-soluble cellulose derivative.
  • examples of the water-soluble cellulose derivative include methyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose and the like.
  • examples of the water-soluble vinyl polymer derivative include polyvinyl alcohol and polyvinyl pyrrolidone.
  • examples of the water-soluble acrylic acid copolymer include acrylic acid polymer, acrylic ester polymer, and methacrylic ester polymer.
  • examples of the polyhydric alcohol polymer include macrogol and polyglycerin.
  • examples of the copolymer include polyvinyl alcohol / acrylic acid / methyl methacrylate copolymer, polyethylene glycol / polyvinyl alcohol graft copolymer, vinyl pyrrolidone / vinyl alcohol copolymer, and the like.
  • water-soluble polymer a water-soluble cellulose derivative selected from the group consisting of hydroxypropylmethylcellulose and hydroxypropylcellulose is preferable from the viewpoint of viscosity and binding property suitable for fine particle coating.
  • a commercially available product may be used as the water-soluble polymer.
  • copolymer polymers examples include polyvinyl alcohol / acrylic acid / methyl methacrylate copolymer (trade name: POVACOAT, manufactured by Daido Kasei Kogyo Co., Ltd.), polyethylene glycol / polyvinyl alcohol graft copolymer ( Trade name: Kollicoat IR, manufactured by BASF), vinylpyrrolidone / vinyl alcohol copolymer (trade name: Kollicoat VA64, manufactured by BASF), and the like.
  • Examples of the water-insoluble film include films formed of components such as a water-insoluble cellulose ether and a water-insoluble acrylic acid copolymer.
  • Examples of the water-insoluble cellulose ether include ethyl cellulose.
  • Examples of the water-insoluble acrylic acid copolymer include ethyl acrylate / methyl methacrylate / methacrylated trimethylammonium ethyl copolymer, ethyl acrylate / methyl methacrylate copolymer, and the like.
  • Commercially available products can also be used as the water-insoluble cellulose ether and the water-insoluble acrylic acid copolymer.
  • Examples of commercially available water-insoluble cellulose ethers include ethylcellulose aqueous dispersions (trade name: Aquacoat ECD, manufactured by FMC).
  • Examples of commercially available water-insoluble acrylic acid copolymers include ethyl acrylate / methyl methacrylate / methacrylated trimethylammonium ethyl copolymer (trade name: Eudragit RS, manufactured by Evonik), ethyl acrylate / methacrylic acid. Examples thereof include a methyl copolymer dispersion (trade name: Eudragit NE30D, manufactured by Evonik).
  • the water-insoluble film may be formed by using any one component alone, or a combination of two or more components having different properties or two or more components having different properties. May be formed.
  • the water-insoluble film can be formed to have a multilayer structure.
  • the content of the water-insoluble film can be 5% by mass to 70% by mass, 10% by mass to 60% by mass, 15% by mass to 50% by mass, etc. with respect to the total mass of the fine granules.
  • the elution control layer may be formed using a combination of two or more components having different properties from the membrane components according to the purpose.
  • the elution control layer can be formed so as to have a multilayer structure.
  • a plurality of elution control layer coating solutions with different compositions etc. are divided into a plurality of times for each elution control layer coating solution. What is necessary is just to spray on a composite component with this component.
  • the elution control layer may contain other components in addition to the polymer as long as the effects of the present invention are not impaired.
  • other components include excipients, binders, lubricants, fluidizers, and plasticizers.
  • specific examples of the excipient include sugar, sugar alcohol, crystalline cellulose, starch and the like.
  • examples of the sugar include lactose, sucrose, maltose, trehalose, dextrin and the like.
  • sugar alcohol include mannitol, erythritol, isomalt, lactitol, maltitol, sorbitol, xylitol and the like.
  • starch include corn starch, potato starch, rice starch, wheat starch and the like.
  • binder examples include hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone and the like.
  • lubricant and the fluidizing agent examples include talc and light anhydrous silicic acid.
  • plasticizer examples include triethyl citrate, polyethylene glycol, polyoxyethylene sorbitan monooleate, acetyl triethyl citrate, tributyl citrate, and tributyl acetyl citrate.
  • the form in which the elution control layer covers the intermediate layer may be a state in which the elution control layer exists on at least a part of the surface of the intermediate layer.
  • the elution control layer preferably covers 1/4 or more of the surface of the intermediate layer, more preferably covers 1/2 or more, and most preferably covers the entire surface.
  • the coating amount of the elution control layer when the intermediate layer is coated with the elution control layer is not particularly limited as long as the intermediate layer is coated in the elution control layer.
  • the mass of the elution control layer used for coating the intermediate layer is 0.01 to 20 times, 0.1 to 15 times, or 0.3 times the total mass of the intermediate layer. The amount is up to 10 times.
  • a plurality of elution control layer coating liquids having different compositions may be sprayed on the intermediate layer in a plurality of times for each elution control layer coating liquid.
  • the orally disintegrating tablet includes fine granules containing a drug substance including a drug substance-containing nucleus, an intermediate layer and an elution control layer, and an excipient outside the fine granules.
  • the fine granules can contain other pharmacologically acceptable additives for pharmaceutical preparation.
  • compositions include binders such as hydroxypropylcellulose and hydroxypropylmethylcellulose, excipients such as mannitol and lactose, lubricants such as talc and glyceryl monostearate, low-substituted hydroxypropylcellulose, partial
  • disintegrants such as alpha starch
  • known ingredients can be used as additives for pharmaceutical preparations generally used in the manufacture of pharmaceuticals such as sweeteners, flavoring agents, fluidizing agents, flavoring agents, and coloring agents.
  • Ingredients known as pharmaceutical additives include ingredients that can function as binders, excipients, lubricants, disintegrants, etc. Even if one ingredient is responsible for two or more functions Good.
  • excipient can be used as the extra-fine-grain excipient as long as it is a component that can function as an excipient.
  • excipients other than fine granules include sugar, sugar alcohol, crystalline cellulose, anhydrous calcium phosphate, magnesium aluminate metasilicate, and the like.
  • sugar examples include lactose, sucrose, maltose, trehalose, dextrin and the like.
  • sugar alcohol examples include D-mannitol, erythritol, isomalt, lactitol, maltitol, sorbitol, xylitol and the like.
  • the sugar alcohol is preferably a sugar alcohol selected from the group consisting of D-mannitol and erythritol.
  • a commercial item can also be used for crystalline cellulose.
  • Examples of commercially available crystalline cellulose include Theolas (trade name, manufactured by Asahi Kasei Chemicals Corporation), Pharmacel (trade name, manufactured by DFE Pharma) and the like.
  • the excipient any one of the excipients may be used alone, or two or more kinds thereof may be used in combination.
  • the content of the excipient can be appropriately determined in consideration of the type of the active ingredient, the content of the active ingredient, the daily dose of the active ingredient, the particle size of the fine particles, and the like.
  • As the disintegrant a known disintegrant can be used as long as it can function as a disintegrant.
  • the disintegrant examples include starch such as corn starch and potato starch, partially pregelatinized starch, sodium carboxymethyl starch, carmellose, carmellose calcium, croscarmellose sodium, crospovidone, low-substituted hydroxypropylcellulose, crystalline cellulose, Examples include hydroxypropyl starch.
  • the disintegrant is more preferably a disintegrant selected from the group consisting of crospovidone, croscarmellose sodium, and low-substituted hydroxypropylcellulose.
  • any one disintegrating agent may be used alone, or two or more disintegrating agents may be used in combination.
  • the content of the disintegrant can be appropriately determined in consideration of the type of the active ingredient, the content of the active ingredient, the daily dose of the active ingredient, the particle diameter of the fine particles, and the like.
  • any known lubricant can be used as long as it can function as a lubricant. Examples of the lubricant include sodium stearyl fumarate, magnesium stearate, calcium stearate and the like. Sodium stearyl fumarate can be obtained as a commercial product from, for example, JRS PHARMA. Any one lubricant may be used alone, or two or more lubricants may be used in combination.
  • the content of the lubricant can be appropriately determined in consideration of the type of the active ingredient, the content of the active ingredient, the daily dose of the active ingredient, the particle size of the fine particles, and the like.
  • the binder include hydroxypropylcellulose, hydroxypropylmethylcellulose, low-substituted hydroxypropylcellulose, carboxyvinyl polymer, carmellose sodium, pregelatinized starch, polyvinylpyrrolidone, gum arabic powder, gelatin, pullulan, polyvinyl alcohol and the like. Any one binder may be used alone, or two or more binders may be used in combination.
  • the content of the binder can be appropriately determined in consideration of the type of the active ingredient, the content of the active ingredient, the daily dose of the active ingredient, the particle diameter of the fine particles, and the like.
  • the additive for formulation may be used individually by 1 type, and may use 2 or more types together.
  • the content of the formulation additive can be appropriately determined in consideration of the type of the active ingredient, the content of the active ingredient, the daily dose of the active ingredient, the particle size of the fine particles, and the like.
  • the average particle diameter of the fine particles is preferably 1 mm or less, more preferably 750 ⁇ m or less, and further preferably 500 ⁇ m or less.
  • the average particle diameter of the fine particles is preferably 50 ⁇ m or more, more preferably 150 ⁇ m or more, and further preferably 300 ⁇ m or more.
  • Fine granules can be prepared according to known methods such as granulating drug substance-containing nuclei, coating the granulated drug substance-containing nuclei with an intermediate layer, and covering the coated intermediate layer with an elution control layer. it can.
  • the method of granulating the drug substance-containing nuclei, the method of coating the granulated drug substance-containing nuclei with an intermediate layer, the method of coating the coated intermediate layer with an elution control layer, etc. are not particularly limited, and known methods Can be used.
  • Examples thereof include a fluidized bed granulation method, a stirring granulation method, a wet granulation method such as spray drying, a dry granulation method such as a compression granulation method, and a pulverization granulation method.
  • Examples of the granulator that can be used in the fluidized bed granulation method include a fluidized bed granulator (product name: FD-MP-01, manufactured by POWREC), a flow coater (product name: FL-1, Freund). Sangyo Co., Ltd.).
  • the orally disintegrating tablet of the present invention comprises fine granules containing the drug substance and excipients (excipients outside the fine granules).
  • excipients include disintegrants, lubricants, excipients, binders, sweeteners, flavoring agents, fluidizing agents, flavoring agents, coloring agents, and other preparations commonly used in the manufacture of pharmaceuticals.
  • Known ingredients may be included as additives for use.
  • the disintegrant a known disintegrant can be used as long as it can function as a disintegrant.
  • starch such as corn starch and potato starch, partially pregelatinized starch, sodium carboxymethyl starch, carmellose, carmellose calcium, croscarmellose sodium, crospovidone, low substituted hydroxypropyl cellulose, crystalline cellulose, hydroxypropyl starch, etc.
  • the disintegrant is more preferably a disintegrant selected from the group consisting of crospovidone, croscarmellose sodium, and low-substituted hydroxypropylcellulose.
  • the disintegrating agent any one disintegrating agent may be used alone, or two or more disintegrating agents may be used in combination.
  • any known lubricant can be used as long as it can function as a lubricant.
  • the lubricant include sodium stearyl fumarate, magnesium stearate, calcium stearate, sucrose fatty acid ester and the like.
  • Sodium stearyl fumarate can be obtained as a commercial product from, for example, JRS PHARMA. Any one lubricant may be used alone, or two or more lubricants may be used in combination.
  • excipient known excipients can be used as long as they can function as excipients.
  • the excipient include sugar, sugar alcohol, crystalline cellulose, anhydrous calcium hydrogen phosphate, magnesium aluminate metasilicate, and the like.
  • the sugar alcohol include mannitol, erythritol, isomalt, lactitol, maltitol, sorbitol, xylitol and the like.
  • a sugar alcohol selected from the group consisting of mannitol and erythritol is preferable from the viewpoint of solubility of the orally disintegrating tablet.
  • a commercial item can also be used for crystalline cellulose. Examples of commercially available crystalline cellulose include Theolas (trade name, manufactured by Asahi Kasei Chemicals Corporation), Pharmacel (trade name, manufactured by DFE Pharma) and the like.
  • binder examples include hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxyvinyl polymer, carmellose sodium, pregelatinized starch, polyvinylpyrrolidone, gum arabic powder, gelatin, pullulan, polyvinyl alcohol and the like.
  • the additive for formulation may be used individually by 1 type, and may use 2 or more types together.
  • the content of the formulation additive can be appropriately determined in consideration of the type of the active ingredient, the content of the active ingredient, the daily dose of the active ingredient, the particle size of the fine particles, and the like.
  • the content of clopidogrel sulfate or rabeprazole sodium in one orally disintegrating tablet can be appropriately determined in consideration of the lower limit and upper limit of the daily dose of clopidogrel sulfate or rabeprazole sodium.
  • the size and shape of the orally disintegrating tablet are not particularly limited as long as it is a pharmaceutically acceptable size and shape.
  • the size of the orally disintegrating tablet includes a diameter of 7 mm to 12 mm, a thickness of 3.0 mm to 7.0 mm, preferably a diameter of 8 mm to 11 mm, and a thickness of 3.5 mm to 6.5 mm. .
  • the size of the orally disintegrating tablet includes a minor axis of 4 mm to 8 mm, a major axis of 8 mm to 18 mm, preferably a minor axis of 4 mm to 6.5 mm, a major axis of 8 mm to 15 mm, and a thickness of 3.0 mm. 7.0 mm, preferably 3.5 mm to 6.5 mm.
  • the hardness of the orally disintegrating tablet is not particularly limited.
  • the hardness of the orally disintegrating tablet is preferably 20 N / m 2 or more and 100 N / m 2 or less, as measured with a tablet hardness meter, from the viewpoint of disintegration, transport stability, availability of an automatic packaging machine, and the like.
  • / m is more preferably 2 or more 70N / m 2 or less.
  • the hardness of the orally disintegrating tablet is measured using a tablet hardness tester Model 8M manufactured by Schleuniger.
  • the disintegration time is defined as the time during which it was confirmed that a part of the tablet disintegrated in the oral cavity.
  • the disintegration time of the orally disintegrating tablet is preferably less than 30 seconds, and more preferably less than 20 seconds.
  • the method for producing the orally disintegrating tablet is not particularly limited, and a known method can be used.
  • Orally disintegrating tablets for example, enteric fine granules and pharmaceutical additives such as disintegrants, lubricants, excipients, binders, etc. are mixed to obtain a mixture, and the resulting mixture is obtained. It can be obtained by tableting with a tableting machine.
  • the method for mixing the fine particles and the excipient is not particularly limited.
  • the fine granules and the excipient may be mixed using a known mixer such as a V-type mixer (made by Tsutsui Rika Kikai Co., Ltd.) or a fluidized bed granulator (made by Paulek Co., Ltd.). it can.
  • the method for tableting the obtained mixture is not particularly limited.
  • the resulting mixture can be tableted using, for example, a known tableting machine such as a rotary tableting machine (product name HT-P18A, manufactured by Hata Seiko Co., Ltd.).
  • Example 1 Preparation of drug substance-containing nucleus 390 g of spherical spherical granules of 50 to 150 ⁇ m and 65 g of clopidogrel sulfate of mannitol (Freund Sangyo Co., Ltd.) and a spouted fluidized bed granulator (trade name FD-MP-01, manufactured by Paulec Co., Ltd.
  • Fluidized bed granulator (Hereinafter referred to as “fluidized bed granulator”), adjusted to a supply temperature of 60 ° C., an exhaust temperature of about 35 ° C., and a liquid speed of 2 g / min to 3 g / min, Granulation was performed by adding the bulk powder of clopidogrel sulfate while spraying the drug layer spray liquid into the fluidized bed granulator. The addition of the bulk powder of clopidogrel sulfate was carried out 16 times in a total of 360 g at a rate of 4 g / min to 8 g / min from 25 minutes after the start of liquid feeding.
  • Granulation was carried out again while spraying into the granulator and adding the bulk powder of clopidogrel sulfate.
  • the addition of the bulk powder of clopidogrel sulfate was performed in a total of 620 g divided into 31 times at a rate of 4 g / min from 10 minutes after the start of liquid feeding.
  • granulation was performed so that the feed rate of the drug substance layer spray liquid during the addition of the bulk powder of clopidogrel sulfate was 593.1 g.
  • the granulated product obtained above was passed through a round sieve (100 ⁇ m) of No. 149, and the granulated product that did not pass through was collected to obtain a drug substance-containing nucleus.
  • intermediate layer coating particles 600 g of drug substance-containing nuclei are charged into a fluidized bed granulator, adjusted to a supply temperature of 60 ° C., an exhaust temperature of about 35 ° C., and a liquid speed of 2 g / min to 3 g / min. 1387.5 g (specified amount) of the intermediate layer spray solution was spray coated to obtain intermediate layer coated particles.
  • Preparation of gastric soluble granules 650g of intermediate layer coating particles are charged into a fluidized bed granulator, the air supply temperature is set to room temperature, the liquid speed is adjusted to 2g / min to 3g / min, and the elution control layer spray having the following composition prepared in advance is prepared. At the time when 2232.1 g (specified amount) of liquid was sprayed into the fluidized bed granulator, the granulation was stopped and the granulated material was recovered.
  • this tableting powder (mixed powder) is 10.5 mm ⁇ , two-stage R-side punch so that 75 mg of clopidogrel is contained in each tablet.
  • Example 1 The mass of one orally disintegrating tablet obtained in Example 1 was 444 mg, and the content of clopidogrel was 75 mg.
  • the orally disintegrating tablet obtained in Example 1 had an average particle diameter of the drug substance-containing nucleus of 197 ⁇ m, and the finished gastric fine granules had an average particle diameter of 251 ⁇ m.
  • the tablet diameter of the orally disintegrating tablet obtained in Example 1 was 10.5 mm ⁇ , and an orally disintegrating tablet with a good tablet size was obtained.
  • the orally disintegrating tablet obtained in Example 1 was actually contained in the mouth and the taste and feeling of taking were evaluated, the extremely strong bitterness of the drug substance was masked for 30 seconds or more, and in the mouth when 30 seconds passed. It was confirmed that the tablet was disintegrated.
  • the content of clopidogrel sulfate in the drug substance layer of the orally disintegrating tablet obtained in Example 1 was 92.2% by mass, and 17.0% by mass in one tablet.
  • the drug substance content rate decreases, so that both the tablet mass and the tablet diameter increase in calculation as shown in Table 1.
  • Table 1 shows a trial calculation when the tablet shape is assumed to be similar even when the tablet mass is increased, based on the same 10.5 mm ⁇ as in Example 1 for the tablet diameter.
  • the tablet diameter is set in increments of 0.5 mm. Since the feeling of administration decreases as the tablet diameter increases, the drug substance content in the drug substance layer (the drug substance layer drug substance content) is preferably higher. In the prescriptions of the examples, since the drug substance content is less than 70% by mass, the drug content tends to decrease due to the increase in tablet diameter, so the drug substance content in the drug substance layer is 70% by mass. % Or more is preferable.
  • Example 2 An orally disintegrating tablet was produced by the same production method as in Example 1 using clopidogrel sulfate having different average particle diameters of the drug substance powder.
  • the particle size distribution of the drug substance powder used in Example 1 and Example 2 is shown in FIGS. 1 and 2, the vertical axis represents the frequency volume ratio (%), and the horizontal axis represents the average particle diameter ( ⁇ m) of the drug substance powder.
  • Example 2 the average particle size of the drug substance-containing nucleus was 189 ⁇ m, and the average particle size of the finished fine granules was 253 ⁇ m.
  • the tablet diameter of the orally disintegrating tablet obtained in Example 2 was 10.5 mm ⁇ , and an orally disintegrating tablet with a good tablet size was obtained.
  • the orally disintegrating tablet obtained in Example 2 was actually included in the mouth and the taste and feeling of taking were evaluated, the extremely strong bitterness of the drug substance was masked for 30 seconds or more, and when 30 seconds had elapsed. It was confirmed that the tablet was disintegrated in the mouth.
  • Table 2 shows the stability evaluation results of the orally disintegrating tablets obtained in Example 1 and Example 2.
  • Example 3 Preparation of drug substance-containing nucleus 390 g of spherical spheres of mannitol 50 g to 150 ⁇ m and 65 g of clopidogrel sulfate are charged into a fluidized bed granulator, the supply temperature is 60 ° C., the exhaust temperature is about 35 ° C., the liquid speed is 2 g / min to 3 g / Granulation was carried out by adding the bulk powder of clopidogrel sulfate while spraying a pre-prepared drug substance layer spray solution having the following composition into a fluid bed granulator.
  • the addition of the bulk powder of clopidogrel sulfate was carried out 16 times in a total of 360 g at a rate of 4 g / min to 8 g / min after 30 minutes from the start of liquid feeding. Before adding, collect a part of the granulated material in the fluidized bed granulator and pass it through a round sieve (53 ⁇ m) of No. 280, and confirm that the proportion of the granulated material passed is 5% or less. did. In addition, granulation was performed so that the feed rate of the drug substance layer spray liquid during the addition of the bulk powder of clopidogrel sulfate was 344.1 g to obtain a drug substance-containing nucleus.
  • the drug substance-containing nucleus obtained in Example 3 has a rough surface, the drug substance adheres or aggregates to form a drug substance layer, and the drug substance layer is in the form of particles. It can be seen that it contains clopidogrel sulfate. Similarly, it can be confirmed that the drug substance-containing nuclei of Example 1, Example 2, and Example 4 described later contain particulate drug substances. On the other hand, as shown in FIG. 4, it can be seen that the drug substance-containing nucleus obtained in Comparative Example 1 has a glossy surface and is smooth.
  • Example 4 Preparation of drug substance-containing nucleus 252.7 g of granulated mannitol, talc, and hydroxypropyl cellulose having a particle size of 150 ⁇ m to 250 ⁇ m, 96.9 g of talc, and 100 g of rabeprazole sodium were charged into a fluidized bed granulator, and an air supply temperature of 60 ° C. The exhaust gas temperature was adjusted to about 30 ° C. and the liquid speed was adjusted to 2 g / min to 3 g / min, and granulation was performed by adding the raw powder of rabeprazole sodium while spraying the drug substance layer spray liquid having the following composition prepared in advance.
  • the raw powder of rabeprazole sodium was added in a total of 300 g in 10 portions at a rate of 1 g / min to 2 g / min after 42 minutes from the start of liquid feeding. Before adding, collect a part of the granulated material in the fluidized bed granulator and pass it through a round sieve (53 ⁇ m) of No. 280, and confirm that the proportion of the granulated material passed is 5% or less. did. In addition, granulation was performed so that the feed rate of the drug substance layer spray liquid during the addition of the raw powder of rabeprazole sodium was 669 g to obtain a drug substance-containing nucleus. Subsequently, 200 g (a prescribed amount) of the intermediate layer 1a spray liquid having the following composition prepared in advance was spray coated, and then dried at a supply air temperature of 80 ° C. for 30 minutes.
  • intermediate layer coating particles 387.5 g of drug substance-containing nuclei are charged into a fluidized bed granulator and adjusted at an air supply temperature of 60 ° C., an air supply rate of 40 m 3 / h to 50 m 3 / h, and a liquid speed of about 5 g / min
  • 2084.4 g of the intermediate layer 1b spray solution having the following composition prepared in advance 2406.4 g of the intermediate layer 2 spray solution, and 916.9 g of the intermediate layer 3 spray solution
  • Drying was carried out at a temperature of 80 ° C. for 75 minutes.
  • the obtained granulated product was sieved with a No. 42 round sieve (355 ⁇ m) and a No. 60 round sieve (250 ⁇ m) to obtain intermediate layer coated particles.
  • enteric fine granules 400 g of intermediate layer coating particles are charged into a fluidized bed granulator, the supply temperature is 40 to 60 ° C., the supply air volume is 50 m 3 / h to 70 m 3 / h, and the liquid speed is 5 g / min to 10 g / min. 653 g of enteric layer 1 spray solution of the following composition prepared in advance, 5100 g of enteric layer 2 spray solution, and 519 g of mannitol solution were spray-coated in order, and the air supply temperature remained at 60 ° C. Drying was performed for 60 minutes, and drying was further performed at an air supply temperature of 80 ° C for 60 minutes. The obtained granulated product was passed through a No. 30 round sieve (500 ⁇ m) and a No. 42 round sieve (355 ⁇ m) to obtain enteric fine granules (fine granules containing the drug substance).
  • Methacrylic acid copolymer LD (30% by weight aqueous dispersion) 266.7 parts, ethyl acrylate / methyl methacrylate copolymer dispersion (30% by weight aqueous dispersion) 66.7 parts, triethyl citrate 10 parts, glyceryl monostearate 6 parts, polysorbate 80 1.5 parts, anhydrous citric acid Acid 0.025 parts, yellow iron sesquioxide 0.1 parts, purified water 422 parts
  • a tableting powder 346.50 parts of the obtained excipient and 231.0 parts of fine granules were mixed to obtain a tableting powder (mixed powder).
  • the obtained tableting powder (mixed powder) was tableted with a tableting machine (RIVA SA, manufactured by PICCOLA NOVA B-10) with a 9.5 mm ⁇ , two-step R-side punch, and disintegrated in the oral cavity. I got a tablet.
  • intermediate layer coated particles 600 g of drug substance-containing nuclei were charged into a fluidized bed granulator and adjusted at a supply air temperature of about 60 ° C., a supply air volume of 40 m 3 / h to 50 m 3 / h, and a liquid speed of about 5 g / min. 419 g of the intermediate layer 1b spray solution having the following composition prepared in advance and 1115 g of the intermediate layer 2 spray solution were spray-coated on the drug substance-containing core in this order, followed by drying at an air supply temperature of 80 ° C. for 30 minutes.
  • the obtained granulated product was sieved with a round sieve of No. 42 (355 ⁇ m) and a round sieve of No.
  • intermediate layer coated particles (1) 600 g to a fluidized bed granulator, inlet air temperature 60 ° C., supply air volume 40m 3 / h ⁇ 50m 3 / h, adjusted with a flow rate of about 5 g / min, previously prepared following
  • drying was performed at a supply air temperature of 80 ° C. for 30 minutes.
  • the obtained granulated product was sieved with a No. 42 round sieve (355 ⁇ m) and a No. 60 round sieve (250 ⁇ m) to obtain intermediate layer coated particles.
  • enteric fine granules 500 g of intermediate layer coating particles are charged into a fluidized bed granulator, the supply temperature is 40 to 60 ° C., the supply air volume is 50 m 3 / h to 70 m 3 / h, the liquid speed is 5 g / min to 10 g / min. 677 g of enteric layer 1 spray solution having the following composition prepared in advance, 5163 g of enteric layer 2 spray solution, and 504 g of mannitol solution were spray-coated on the intermediate layer coating particles in this order, and then the air supply temperature It dried for 60 minutes with 60 degreeC, and also dried for 60 minutes by making supply air temperature into 80 degreeC. The obtained granulated product was passed through a No. 30 round sieve (500 ⁇ m) and a No. 42 round sieve (355 ⁇ m) to obtain enteric fine granules (fine granules containing the drug substance).
  • Methacrylic acid copolymer LD (30% by weight aqueous dispersion) 266.7 parts, ethyl acrylate / methyl methacrylate copolymer dispersion (30% by weight aqueous dispersion) 66.7 parts, triethyl citrate 10 parts, glyceryl monostearate 6 parts, polysorbate 80 1.5 parts, anhydrous citric acid Acid 0.025 parts, yellow iron sesquioxide 0.1 parts, purified water 422 parts
  • Example 3 Evaluation of stability Decomposition product generation rate after thermal aging of Example 3 and Comparative Example 1 and Example 4 and Comparative Example 2, average particle diameter of drug substance-containing nuclei (measured by laser diffraction particle size distribution measurement method) Table 3 shows the drug substance content of the drug substance layer.
  • the degradation product formation rate was determined by subtracting the peak area% of the drug substance after the lapse of time from the peak area% of the drug substance after manufacture by HPLC analysis.
  • the fine particles obtained in Comparative Example 1 had strong adhesion, and the average particle size could not be measured by the above method, so the average particle size was measured from a photomicrograph.
  • Example 3 and Example 4 in which the drug substance was granulated as a solid, the degradation product generation rate was lower than in Comparative Example 1 and Comparative Example 2 in which the drug substance was dissolved and granulated. It is considered that the stability of the drug substance was improved by granulating the solid.
  • Example 5 Preparation of drug substance-containing nuclei 300 g of spherical spherical granules of 150 to 250 ⁇ m, 100 g of talc and 50 g of clopidogrel sulfate of mannitol (Freund Sangyo Co., Ltd.) are charged into a spouted fluidized bed granulator, and the supply temperature is 60 ° C. and the exhaust temperature is Granulated by adding the bulk powder of clopidogrel sulfate while spraying the pre-prepared drug substance layer spray liquid in the fluidized bed granulator at about 35 ° C and liquid speed of 1g / min to 2g / min. Went.
  • the addition of the bulk powder of clopidogrel sulfate was carried out in a total of 640 g divided into 22 portions at a rate of 4 g / min to 8 g / min 30 minutes after the start of liquid feeding. Before adding, collect a part of the granulated material in the fluidized bed granulator and pass it through a round sieve (53 ⁇ m) of No. 280, and confirm that the proportion of the granulated material passed is 5% or less. did. In addition, granulation was performed so that the feed rate of the drug substance layer spray liquid during the addition of the bulk powder of clopidogrel sulfate was 241.6 g.
  • 500 g of the granulated product obtained above is charged into a fluidized bed granulator and adjusted to a supply temperature of 60 ° C., an exhaust temperature of about 35 ° C., and a liquid speed of 2 g / min to 4 g / min.
  • Granulation was carried out again while spraying into the granulator and adding the bulk powder of clopidogrel sulfate.
  • the addition of the bulk powder of clopidogrel sulfate was carried out 24 times in a total of 960 g at a pace of 8 g / min from 10 minutes after the start of liquid feeding.
  • intermediate layer coating particles 600 g of drug substance-containing nuclei were charged into a fluidized bed granulator, adjusted to an air supply temperature of 60 ° C., an exhaust temperature of about 35 ° C., and a liquid speed of 2 g / min to 3 g / min.
  • the intermediate layer spray solution 617.0 g (specified amount) was spray coated to obtain intermediate layer coated particles.
  • Preparation of gastric soluble granules 650g of intermediate layer coating particles are charged into a fluidized bed granulator, the air supply temperature is set to room temperature, the liquid speed is adjusted to 2g / min to 3g / min, and the elution control layer spray having the following composition prepared in advance is prepared. When 613.8 g (specified amount) of the liquid was sprayed, the granulation was stopped to obtain a granulated product.
  • this tableting powder (mixed powder) was packed with 8.0 mm ⁇ , two-stage rounded surface so that 75 mg of clopidogrel was contained per tablet. Was tableted to obtain an orally disintegrating tablet. Tableting was performed with the preload thickness and the main pressure thickness kept constant.
  • Example 5 The average particle size of the drug substance-containing core obtained in Example 5 was 404 ⁇ m, and the average particle size of the finished fine granules was 464 ⁇ m.
  • the tablet diameter was 8.0 mm ⁇ , and an orally disintegrating tablet with a good tablet size was obtained.
  • the orally disintegrating tablet obtained in Example 5 was actually included in the mouth, and the taste and feeling of taking were evaluated. It was confirmed that the tablet was disintegrated in the mouth. Moreover, there was little rough feeling by a fine granule and the oral disintegrating tablet with favorable mouthfeel was able to be obtained.
  • Example 6 The orally disintegrating tablet produced in the same manner as in Example 1 was subjected to PTP (Press Through Pack) packaging made of polypropylene without drying.
  • PTP Pressure Through Pack
  • Example 7 The orally disintegrating tablet produced in the same manner as in Example 1 was placed in a closed container together with silica gel, taken out after 8 hours, and subjected to PTP (Press Through Pack) packaging made of polypropylene.
  • PTP Pressure Through Pack
  • Example 8 With respect to the orally disintegrating tablet produced in the same manner as in Example 1, dry air having a relative humidity of 5% or less at a temperature of 25 ° C. was dried with a dry dehumidifier (trade name: Honey Dry, Daikin Co., Ltd.). Air was supplied for 8 hours, and PTP (Press Through Pack) packaging made of polypropylene was applied in a room at a temperature of 25 ° C. and a relative humidity of 5% or less.
  • a dry dehumidifier trade name: Honey Dry, Daikin Co., Ltd.
  • Example 6 The tablets obtained in Examples 6 to 8 were obtained using a Karl Fischer moisture meter (Mitsubishi Chemical Analytech Co., Ltd .; trace moisture measuring device CA-200, moisture vaporizer VA-200).
  • Table 4 shows the water content (% by mass) and the decomposition product generation rate (%) when heat-aging at 70 ° C. for 1 week.
  • the degradation product formation rate was determined by subtracting the peak area% of the drug substance after the lapse of time from the peak area% of the drug substance after manufacture by HPLC analysis.
  • the decomposition product generation rate was approximately halved, and in the dried Example 8, the decomposition product generation rate was further decreased by half. From this result, the moisture content of the tablet at the time of packaging is preferably 1% by mass or less, and more preferably 0.5% by mass or less.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne : un procédé pour produire un noyau contenant une substance médicamenteuse présentant une taille moyenne de particule de 100 à 500 µm, le procédé comprenant la granulation par une charge intermittente ou continue d'une poudre de substance médicamenteuse dans un granulateur à lit fluidisé tout en chargeant par intermittence ou de manière continue un liquide de couplage dans le granulateur à lit fluidisé, les contenus du granulateur à lit fluidisé s'écoulant ; un noyau contenant une substance médicamenteuse ; une composition pharmaceutique ; et un comprimé se désintégrant par voie orale.
PCT/JP2014/075533 2013-09-30 2014-09-25 Procédé pour produire un noyau contenant une substance médicamenteuse, noyau contenant une substance médicamenteuse, composition pharmaceutique et comprimé se désintégrant par voie orale WO2015046383A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015539355A JPWO2015046383A1 (ja) 2013-09-30 2014-09-25 原薬含有核の製造方法、原薬含有核、医薬品組成物、及び口腔内崩壊錠

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2013-205195 2013-09-30
JP2013205195 2013-09-30
JP2014055467 2014-03-18
JP2014-055467 2014-03-18

Publications (1)

Publication Number Publication Date
WO2015046383A1 true WO2015046383A1 (fr) 2015-04-02

Family

ID=52743509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/075533 WO2015046383A1 (fr) 2013-09-30 2014-09-25 Procédé pour produire un noyau contenant une substance médicamenteuse, noyau contenant une substance médicamenteuse, composition pharmaceutique et comprimé se désintégrant par voie orale

Country Status (2)

Country Link
JP (1) JPWO2015046383A1 (fr)
WO (1) WO2015046383A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017183628A1 (fr) * 2016-04-19 2017-10-26 味の素株式会社 Produit granulé et son procédé de fabrication
JP2019011319A (ja) * 2017-06-30 2019-01-24 大鵬薬品工業株式会社 固形製剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0630975A (ja) * 1992-07-17 1994-02-08 Powrex:Kk 高薬物含量粉体の重質造粒法
JP2002095952A (ja) * 2000-09-22 2002-04-02 Freunt Ind Co Ltd 流動層造粒コーティング装置および流動層造粒コーティング方法
JP2010006802A (ja) * 2008-05-28 2010-01-14 Sumitomo Chemical Co Ltd 顆粒状農薬製剤
JP2013010751A (ja) * 2011-05-31 2013-01-17 Sawai Pharmaceutical Co Ltd クロピドグレル含有錠剤及びその製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5503192B2 (ja) * 2009-06-03 2014-05-28 大原薬品工業株式会社 生理活性物質含有粒子の製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0630975A (ja) * 1992-07-17 1994-02-08 Powrex:Kk 高薬物含量粉体の重質造粒法
JP2002095952A (ja) * 2000-09-22 2002-04-02 Freunt Ind Co Ltd 流動層造粒コーティング装置および流動層造粒コーティング方法
JP2010006802A (ja) * 2008-05-28 2010-01-14 Sumitomo Chemical Co Ltd 顆粒状農薬製剤
JP2013010751A (ja) * 2011-05-31 2013-01-17 Sawai Pharmaceutical Co Ltd クロピドグレル含有錠剤及びその製造方法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017183628A1 (fr) * 2016-04-19 2017-10-26 味の素株式会社 Produit granulé et son procédé de fabrication
JPWO2017183628A1 (ja) * 2016-04-19 2019-02-21 味の素株式会社 造粒物およびその製造方法
JP7052722B2 (ja) 2016-04-19 2022-04-12 味の素株式会社 造粒物およびその製造方法
JP2019011319A (ja) * 2017-06-30 2019-01-24 大鵬薬品工業株式会社 固形製剤
JP7162959B2 (ja) 2017-06-30 2022-10-31 大鵬薬品工業株式会社 固形製剤

Also Published As

Publication number Publication date
JPWO2015046383A1 (ja) 2017-03-09

Similar Documents

Publication Publication Date Title
JP5604304B2 (ja) 口腔内崩壊性固形製剤
JP6154019B2 (ja) 口腔内崩壊錠
JP4789806B2 (ja) パントプラゾール多粒子処方
US20080003281A1 (en) Modified Release Tablet Formulations for Proton Pump Inhibitors
JP6976946B2 (ja) 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
JP2016164170A (ja) プロトンポンプ阻害剤を含む制御放出組成物
KR20110008036A (ko) 약 염기성 약물 및 제어 방출 제형을 포함하는 조성물
JPWO2008081891A1 (ja) 口腔内崩壊性固形製剤
US20110027361A1 (en) Extended release dosage form of paliperidone
CA2858941C (fr) Combinaison d'hydrochlorure de benazeprile et de pimobendane
KR20070073867A (ko) 양성자 펌프 억제제를 위한 신규 변형 방출 펠릿 제형
WO2011140446A2 (fr) Formulations pharmaceutiques
JPWO2014181390A1 (ja) 機能性高分子皮膜で被覆された高含量薬物粒子およびそれを含む錠剤ならびにそれらの製造方法
JPWO2012018056A1 (ja) 圧縮組成物
WO2016129140A1 (fr) Comprimé à désintégration intrabuccale rapide et son procédé de fabrication
JP2017048174A (ja) 化学的に安定な原薬含有被覆粒子を含む口腔内崩壊錠剤
WO2015046383A1 (fr) Procédé pour produire un noyau contenant une substance médicamenteuse, noyau contenant une substance médicamenteuse, composition pharmaceutique et comprimé se désintégrant par voie orale
JP2015086194A (ja) ラベプラゾールナトリウム含有粒子の製造方法及びそれを含む医薬組成物
WO2011138797A2 (fr) Composition pharmaceutique de lansoprazole à action différée se désintégrant par la voie buccale
JP6096328B2 (ja) 口腔内崩壊錠
MXPA06002443A (es) Formulaciones inhibidoras de la bomba de protones y metodos para preparar y utilizar tales formulaciones.
MX2008016565A (es) Composiciones farmaceuticas que comprenden una combinacion de piperidinoalcanol y descongestivo.
JP6147711B2 (ja) 医薬用組成物及びその製造方法、並びに口腔内崩壊錠及びその製造方法
JP2015027981A (ja) 腸溶性細粒及び医薬組成物
JP5934835B2 (ja) 腸溶性細粒及び医薬組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14847412

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015539355

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14847412

Country of ref document: EP

Kind code of ref document: A1